SPC 103751
Latest Information Update: 09 Sep 1998
At a glance
- Originator Research Triangle Park Laboratories
- Class
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 09 Sep 1998 Discontinued - Preclinical for Malignant melanoma in USA (unspecified route)
- 16 Sep 1996 Preclinical development for Malignant melanoma in USA (unspecified route)